Transcription of Reference ID: 3860969
{{id}} {{{paragraph}}}
Example: dental hygienist
Reference ID: 3860969
HIGHLIGHTS OF PRESCRIBING INFORMATION Marked Bradycardia: Cases of marked bradycardia, some of which These highlights do not include all the information needed to use have resulted in cardiac arrest, have been observed within minutes BRIDION safely and effectively. See full prescribing information after administration. Monitor for hemodynamic changes and for BRIDION. administer anticholinergic agents such as atropine if clinically significant bradycardia is observed. ( ). BRIDION (sugammadex) Injection, for intravenous use Respiratory Function Monitoring: Ventilatory support is mandatory Initial Approval: 2015 for patients until adequate spontaneous respiration is restored and the ability to maintain a patent airway is assured. Should ----------------------------INDICATIONS AND USAGE ---------------------------- neuromuscular blockade persist after BRIDION or recur following BRIDION is indicated for the reversal of neuromuscular blockade extubation, take appropriate steps to provide adequate ventilation.
in the BRIDION 16 mg/kg group on the first dose). Signs and symptoms included conjuctival edema, n urticaria, erythema, swelling of the uvula and reduction in peak expiratory flow within 5 minutes of dose administration. The most common hypersensitivity adverse reactions reported were nausea, pruritus and
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: